Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 2292 matching drugs for ERBB2 — including drugs targeting any of its 158 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 Direct 3
afatinib ERBB2 Direct yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 Direct 3
trastuzumab emtansine ERBB2 Direct yes 3
tucatinib ERBB2 Direct yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 Direct 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 Direct 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 Direct 2
lapatinib ERBB2 Direct yes 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 Direct 2
trastuzumab ERBB2 Direct yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 Direct 2
trastuzumab, tipifarnib ERBB2 Direct 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 Direct 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 Direct 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 Direct 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 Direct 1
afatinib, docetaxel, radiation therapy ERBB2 Direct 1
afatinib, gefitinib ERBB2 Direct 1
afatinib, irinotecan ERBB2 Direct 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab ERBB2 Direct 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab ERBB2 Direct 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab ERBB2 Direct 1
cetuximab, trastuzumab ERBB2 Direct 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy ERBB2 Direct 1
db-1310, trastuzumab, osimertinib ERBB2 Direct 1
disitamab vedotin, tucatinib ERBB2 Direct 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab ERBB2 Direct 1
docetaxel, oxaliplatin, capecitabine, trastuzumab ERBB2 Direct 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel ERBB2 Direct 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig ERBB2 Direct 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery ERBB2 Direct 1
lapatinib, chemoradiation, placebo ERBB2 Direct 1
lapatinib, placebo ERBB2 Direct 1
lapatinib, placebo, capecitabine, oxaliplatin ERBB2 Direct 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab ERBB2 Direct 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab ERBB2 Direct 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab ERBB2 Direct 1
palbociclib, afatinib ERBB2 Direct 1
pazopanib, lapatinib ERBB2 Direct 1
pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab ERBB2 Direct 1
pembrolizumab, trastuzumab, oxaliplatin, capecitabine ERBB2 Direct 1
tesevatinib ERBB2 Direct 1
tirelizumab, trastuzumab, docetaxel, s1, oxaliplatin ERBB2 Direct 1
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment ERBB2 Direct 1
trastuzumab, pertuzumab, paclitaxel, carboplatin ERBB2 Direct 1
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab ERBB2 Direct 1
tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo ERBB2 Direct 1
zanidatamab, tislelizumab, trastuzumab, capecitabine, oxaliplatin, cisplatin, 5-fluorouracil ERBB2 Direct 1
zongertinib, trastuzumab deruxtecan, trastuzumab emtansine ERBB2 Direct 1
afatinib dimaleate ERBB2 Direct yes 0
dacomitinib ERBB2 Direct yes 0
lanreotide ERBB2 Direct yes 0
lanreotide acetate ERBB2 Direct yes 0
lapatinib ditosylate ERBB2 Direct yes 0
neratinib ERBB2 Direct yes 0
neratinib maleate ERBB2 Direct yes 0
pertuzumab ERBB2 Direct yes 0
trastuzumab deruxtecan ERBB2 Direct yes 0
vandetanib ERBB2 Direct yes 0
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
binimetinib and encorafenib BRAF SSL via BRAF yes 1
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
olaparib PARP2 SSL via PARP2 yes 1
osimertinib EGFR SSL via EGFR yes 1
sunitinib FLT3 SSL via FLT3 yes 5
sunitinib KDR SSL via KDR yes 5
sunitinib KIT SSL via KIT yes 5
sunitinib MET SSL via MET 5
sunitinib PDGFRA SSL via PDGFRA yes 5
sunitinib PDGFRB SSL via PDGFRB yes 5
docetaxel, thalidomide BCL2 SSL via BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BCL2 SSL via BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR2 SSL via FGFR2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR SSL via KDR 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRA SSL via PDGFRA 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRB SSL via PDGFRB 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RAF1 SSL via RAF1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RET SSL via RET 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab VEGFA SSL via VEGFA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR2 SSL via FGFR2 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR SSL via KDR 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRA SSL via PDGFRA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRB SSL via PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RAF1 SSL via RAF1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RET SSL via RET 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR SSL via KDR 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TYMS SSL via TYMS 3
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.